Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

NewAmsterdam Pharma Co N.V (NAMS) EBITDA Margin: 2023-2025

Historic EBITDA Margin for NewAmsterdam Pharma Co N.V (NAMS) over the last 3 years, with Sep 2025 value amounting to -20,601.15%.

  • NewAmsterdam Pharma Co N.V's EBITDA Margin fell 2054396.00% to -20,601.15% in Q3 2025 from the same period last year, while for Sep 2025 it was -626.66%, marking a year-over-year decrease of 3455.00%. This contributed to the annual value of -530.15% for FY2024, which is 72561.00% up from last year.
  • As of Q3 2025, NewAmsterdam Pharma Co N.V's EBITDA Margin stood at -20,601.15%, which was down 22,475.07% from -91.26% recorded in Q2 2025.
  • NewAmsterdam Pharma Co N.V's 5-year EBITDA Margin high stood at -57.18% for Q3 2024, and its period low was -20,601.15% during Q3 2025.
  • Over the past 3 years, NewAmsterdam Pharma Co N.V's median EBITDA Margin value was -1,602.62% (recorded in 2023), while the average stood at -3,789.75%.
  • As far as peak fluctuations go, NewAmsterdam Pharma Co N.V's EBITDA Margin skyrocketed by 544,240bps in 2024, and later crashed by 2,054,396bps in 2025.
  • Quarterly analysis of 3 years shows NewAmsterdam Pharma Co N.V's EBITDA Margin stood at -6,163.76% in 2023, then skyrocketed by 544,240bps to -721.36% in 2024, then crashed by 2,054,396bps to -20,601.15% in 2025.
  • Its EBITDA Margin stands at -20,601.15% for Q3 2025, versus -91.26% for Q2 2025 and -1,328.41% for Q1 2025.